<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/855ACD43-8240-48FB-AF40-C8F87B294B74"><gtr:id>855ACD43-8240-48FB-AF40-C8F87B294B74</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:otherNames>Shaun</gtr:otherNames><gtr:surname>Scrutton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FN012356%2F1"><gtr:id>A4ABC6E6-A136-4930-8A57-A2542C5ECBFC</gtr:id><gtr:title>Feasibility study to determine whether new generation catalytic antibodies can overcome existing limitations for future use in clinical settings.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/N012356/1</gtr:grantReference><gtr:abstractText>Research into the therapeutic use of catalytic antibodies stretches back over 30 years but to date there is not a single example of success in the clinic. This is in stark contrast to the ever-expanding use of antibodies to treat a range of diseases when they are used as binders and modulators of protein function. This feasibility study aims to answer whether this imbalance can be redressed through the utilisation of novel techniques now available in antibody research (specifically improved antibody phage libraries and bispecific antibody technologies) combined with an examination of the therapeutic and commercial potential of catalytic antibodies should the primary issues of poor catalytic efficiency and selectivity as compared to the natural enzymes be addressed. As a test case we have chosen to try and make catalytic antibodies that share the therapeutically useful properties of streptococcal IgG endopeptidase but lack the enzyme's immunogenicity, which seriously limits its clinical potential.</gtr:abstractText><gtr:technicalSummary>Research into the therapeutic use of catalytic antibodies stretches back over 30 years but to date there is not a single example of success in the clinic. This is in stark contrast to the ever-expanding use of antibodies to treat a range of diseases when they are used as binders and modulators of protein function. This feasibility study aims to answer whether this imbalance can be redressed through the utilisation of novel techniques now available in antibody research (specifically improved antibody phage libraries and bispecific antibody technologies) combined with an examination of the therapeutic and commercial potential of catalytic antibodies should the primary issues of poor catalytic efficiency and selectivity as compared to the natural enzymes be addressed. As a test case we have chosen to try and make catalytic antibodies that share the therapeutically useful properties of streptococcal IgG endopeptidase but lack the enzyme's immunogenicity, which seriously limits its clinical potential.</gtr:technicalSummary><gtr:potentialImpactText>As described in proposal submitted to TSB</gtr:potentialImpactText><gtr:fund><gtr:end>2017-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2016-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>119421</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MIB Open Day Stands/Tours</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>94974154-05F3-42F8-8B44-D300E79A8554</gtr:id><gtr:impact>At Institute Open Day members of research group presented exhibits on topics of enzyme catalysis, synthetic biology, light activated biology and 'proteins' in general. Also demonstrated use of laboratory equipment on lab-tours run for attending students. Event was well received by both students and their teachers and seemed to inspire interest in the subject.

No defined impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012,2013,2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/N012356/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0CCE05F7-E409-4D0C-B074-FE53B9DCFB6F</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomedical sciences</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B971A4E6-FF4B-45BC-96D6-1E289961490D</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Catalysis &amp; enzymology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>02567418-12CB-462E-9092-530C6E63B359</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Chemical Biology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>8A1414BC-05E5-4D38-BDC1-A953EE4AF4E1</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Protein chemistry</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>DF4CD176-73D5-4039-BBC7-28D33DC364DD</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Synthetic biology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>